The study, published in Cancer Causes & Control, examined multiple myeloma mortality across the United States from 1999 through 2024 and extended forecasts to 2034. Researchers drew on the CDC Wide-Ranging Online Data for Epidemiologic Research database, identifying myeloma-related deaths with the ICD-10 code C90.0. From these records they calculated age-adjusted mortality rates per one million population, standardized to the 2000 US population, and applied joinpoint regression to detect statistically significant shifts in trend over time. To look forward, they built autoregressive integrated moving average models, selected by the Akaike Information Criterion, projecting rates with 95 percent confidence intervals through 2034.

The headline finding is genuinely encouraging: age-adjusted myeloma mortality fell from 37.6 to 25.1 deaths per million between 1999 and 2024, an average annual decline of 1.8 percent. More striking is when that decline accelerated. The annual percent change dropped to minus 3.2 percent after 2012, a statistical inflection that the authors link directly to the widespread adoption of novel therapeutic agents. That year, landmark trials of lenalidomide maintenance after stem-cell transplantation reshaped standard care, and the subsequent years brought proteasome inhibitor combinations, lenalidomide-based regimens, daratumumab, bispecific antibodies such as teclistamab, and CAR T-cell products like idecabtagene vicleucel into the clinic.

Beneath the encouraging national curve, however, lies a stratified picture that has barely budged in twenty-five years. Men consistently died at far higher rates than women, recording 32.4 deaths per million in 2024 compared with 19.8 for women. Adults aged 65 and older carried the heaviest burden by far, with a mortality rate of 175 per million in 2024, down from 230 in 1999, reflecting both the age-dependent incidence of myeloma and the challenges of treating frail elderly patients with intensive regimens. Geriatric assessment has been shown to predict survival and toxicity in older myeloma patients, yet undertreatment in this population remains a persistent concern.

The starkest disparity is racial. Black or African American individuals experienced the highest myeloma mortality of any group throughout the entire study period, and in 2024 their age-adjusted death rate stood at 48.0 per million, more than double the rate of 23.5 among White individuals. This is not simply a reflection of higher incidence, though Black Americans do develop myeloma more frequently. Prior SEER-Medicare analyses have documented racial differences in treatment patterns and outcomes, and population-based studies have shown that disparities in myeloma incidence and survival track closely with access to specialty care, novel agents, and clinical trial participation. Even as average outcomes improve, the benefits of new drugs appear to accrue faster to populations already closer to centers of excellence.

Geography tells a parallel story of uneven progress. The South and nonmetropolitan counties consistently showed higher mortality than other census regions and metropolitan areas. Rural patients face longer travel distances to hematologists, fewer transplant-capable facilities, and lower enrollment in the clinical trials that have driven recent advances. Analyses of the National Cancer Database have linked hospital facility characteristics and socioeconomic factors to myeloma treatment and outcomes, underscoring that where a patient lives and receives care can matter nearly as much as which drugs exist.

The study also tracked where Americans die of myeloma, an indicator that reflects both end-of-life care patterns and access to hospice. Earlier national work on cancer deaths has documented racial, age, and geographic disparities in place of death, and the broader shift of American deaths from hospitals to homes and hospice facilities has been well described. The persistence of these patterns among myeloma patients suggests that disparities extend beyond drug access into the structure of palliative and supportive care itself.

Looking ahead, the ARIMA projections offer a mixed forecast. National age-adjusted mortality is expected to continue declining, reaching approximately 20.0 per million by 2034, with a confidence interval of 17.5 to 22.5. That trajectory would represent a further one-third reduction from current levels, plausibly driven by bispecific antibodies, CAR T-cell therapy, and the growing arsenal of agents moving into earlier lines of treatment. But the models also indicate that racial, geographic, and sociodemographic gaps are projected to persist essentially unchanged. In other words, if current patterns of access hold, the average American with myeloma will fare better in 2034, while the excess burden borne by Black Americans, rural residents, and Southerners will remain stubbornly intact.

The authors argue that closing these gaps will require more than new molecules. Equitable access to care, earlier diagnosis, and improved representation of underserved populations in clinical research are named as essential complements to therapeutic innovation. Earlier diagnosis is particularly consequential because myeloma is often preceded by identifiable precursor states, and delays in detection disproportionately affect populations with weaker connections to routine medical care. Clinical trial diversity matters because the drugs of the next decade will be calibrated on the populations that test them, and myeloma trials have historically under-enrolled the very groups with the highest disease burden.

For a disease affecting roughly tens of thousands of newly diagnosed Americans each year, the quarter-century record synthesized in this analysis is a testament to how rapidly biomedical science can change survival curves. It is also a cautionary tale about who shares in that progress. The decline in myeloma mortality after 2012 is one of the clearest population-level signatures of the precision medicine era, yet the doubling of death rates between Black and White Americans in 2024 shows that a rising tide of innovation has lifted boats unevenly. As immunotherapies push ever deeper into myeloma treatment, the central policy question the study poses is no longer whether effective drugs exist, but whether the health system can deliver them equitably across the lines of race, age, sex, and geography that this national data set lays so plainly bare.

Subject of Research: National trends and persistent disparities in multiple myeloma mortality in the United States, 1999–2024

Article Title: Two decades of progress, persistent inequity: national trends in multiple myeloma mortality in the United States, 1999–2024

Article References: Two decades of progress, persistent inequity: national trends in multiple myeloma mortality in the United States, 1999–2024. (n.d.). https://doi.org/10.1007/s10552-026-02253-x

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02253-x

Keywords: multiple myeloma, mortality trends, health disparities, CDC WONDER, joinpoint regression, ARIMA forecasting, racial disparities, novel therapies, age-adjusted mortality, health equity, cancer epidemiology, decades

Motor neuron disease encompasses a group of progressive disorders in which the nerve cells that control voluntary muscle movement degenerate and die. The most familiar form is amyotrophic lateral sclerosis, or ALS, but the category also includes other rarer variants. In the study, researchers identified deaths using the International Classification of Diseases, 10th Revision code G12.2 listed as the underlying cause of death. Over the 26-year study window, annual deaths rose from 5,121 in 1999 to 7,551 in 2024, a 47.45 percent increase. On its face, that trajectory might suggest an escalating epidemic. Yet when the researchers adjusted for the changing age structure of the population, a different picture emerged: the age-adjusted mortality rate actually declined slightly, from 2.87 to 2.58 deaths per 100,000 population.

The gap between raw counts and adjusted rates is one of the most instructive technical points in the analysis. Because the American population has aged considerably since 1999, with a rapidly expanding share of adults in the age brackets where motor neuron disease is most common, raw death counts naturally rise even if an individual’s underlying risk does not. Age-adjusted mortality rates correct for this demographic shift by applying observed age-specific death rates to a standard population, allowing like-for-like comparisons across time. The authors used joinpoint regression, a statistical technique that identifies points in time where trends change direction, to estimate annual percentage changes and average annual percentage changes. The result: an overall average annual percentage change of minus 0.50 percent, with a 95 percent confidence interval spanning from minus 1.24 to plus 0.24 percent, a range that includes zero and therefore indicates no statistically clear long-term increase or decrease.

Beneath that overall stability, however, the mortality burden was far from evenly distributed. Deaths were heavily concentrated among adults aged 65 years and older, among men, and among non-Hispanic White individuals. These demographic patterns are consistent with much of the prior epidemiological literature on motor neuron disease, which has repeatedly noted both older age at onset and a modest male predominance. For age-group analyses, the researchers used crude mortality rates specific to each age band, since age adjustment is unnecessary when comparing within a single age stratum. For all other stratifications, including sex, race and ethnicity, census region, state, and level of urbanization, the age-adjusted mortality rate served as the primary metric.

Geography told its own revealing story. The South recorded the largest total number of motor neuron disease deaths, a finding shaped partly by the sheer size of that region’s population. But when rates rather than counts were compared, it was the Midwest that carried the highest age-adjusted mortality rate. The distinction matters: total counts reflect population size, while rates reflect underlying risk after demographic correction. A parallel pattern emerged along the urban-rural divide. In analyses covering 1999 through 2020, the most recent period for which urbanization classifications were available, age-adjusted mortality rates were consistently higher in nonmetropolitan areas than in metropolitan ones. The authors stress, however, that these stratified and state-level results should be interpreted as descriptive and exploratory rather than as evidence of causal differences between places.

Why might rural areas show elevated rates? The study itself does not test explanations, but the rural-metropolitan gap aligns with plausible hypotheses that researchers have long considered, including differences in occupational exposures, environmental factors, healthcare access, and diagnostic patterns. Rural populations tend to be older on average, and access to neuromuscular specialists and advanced diagnostic resources is often thinner outside major metropolitan centers, factors that could influence both true disease occurrence and the likelihood that a death is correctly attributed to motor neuron disease on a death certificate. Death-certificate data, while invaluable for tracking long-term and geographic patterns, are inherently subject to coding practices that may vary across providers, regions, and eras.

The methodological architecture of the study is worth appreciating. CDC WONDER aggregates Underlying Cause of Death data from the National Center for Health Statistics, providing publicly available, anonymous, aggregate-level mortality records covering the entire United States. Because the data are de-identified and population-level, the analysis required no institutional review board approval and involved no contact with individual participants. Serial cross-sectional designs like this one examine the population at repeated time points, stitching together annual snapshots into a long-term trend line. The trade-off is that such designs capture mortality patterns but cannot follow individuals forward in time, which limits causal inference. The authors are explicit that their findings describe patterns, not mechanisms, and that the state-level and stratified results are exploratory.

The practical implications lean heavily toward planning and resource allocation. The authors conclude that even with stable age-adjusted rates, the needs associated with motor neuron disease-related medical care, respiratory support, rehabilitation management, and public health services are likely to keep growing as the population ages. Motor neuron disease is relentlessly progressive: as motor neurons die, patients lose the ability to walk, speak, swallow, and eventually breathe, making multidisciplinary care, ventilatory support, and rehabilitation central to management. A rising volume of cases, driven by demography rather than by any change in per-person risk, translates directly into rising demand for neurologists, pulmonologists, respiratory therapists, physical and occupational therapists, palliative care teams, and caregiver support networks, particularly in the regions and community types where the registered burden is heaviest.

The study also illustrates a broader lesson for how health statistics should be read in an aging society. Raw counts of deaths from age-related diseases will climb in nearly every developed country simply because more people are living into the risk window. Age-adjusted rates are the tool that separates real changes in risk from demographic arithmetic, and here they suggest that the United States has not experienced a clear long-term escalation in motor neuron disease mortality risk per person over the past quarter century. That is not a cause for complacency; the absolute and growing number of affected families, the concentrated burden among older adults, and the persistent geographic and demographic disparities all demand sustained attention. But it reframes the narrative: America’s motor neuron disease challenge is primarily a story of population aging and uneven distribution, not of a sharply worsening underlying toll.

For researchers, the analysis sets a benchmark against which future studies can be measured. The slightly declining point estimate, with confidence intervals that straddle zero, leaves open the possibility of small increases or small decreases that larger or more granular datasets might resolve. Continued surveillance will be needed to track whether the expansion of therapies for ALS, improvements in supportive and respiratory care, and lengthening survival times alter mortality patterns in the decades ahead, since better management can extend life and, paradoxically, reshape how deaths are counted and classified. For now, the study provides clinicians, policymakers, and public health planners with a rigorous, nationally representative map of where and among whom motor neuron disease deaths occur, and a clear signal that the systems built to care for these patients must scale with the demographics of the country rather than with the per-capita rate alone.

One nuance worth noting is that the underlying cause of death on a certificate may not capture the full contribution of motor neuron disease to a person’s decline. Because respiratory failure is the usual terminal event, some deaths in which the condition was a contributing factor may be coded to other causes, meaning the figures here likely represent a conservative floor rather than a ceiling of the true mortality burden. The restriction to a single ICD-10 code also means that deaths classified under related codes would fall outside the count, a limitation the authors implicitly acknowledge by framing their results around registered mortality.

The demographic concentration among non-Hispanic White individuals also invites careful reading. Such patterns can reflect a mix of true differences in disease occurrence, differences in age structure across racial and ethnic groups, and differences in diagnostic access and certification practices. Disentangling those threads requires data sources richer than aggregate death records, such as population-based disease registries that capture incidence, survival, and treatment exposure rather than death alone.

Finally, the flat age-adjusted trend should not be read as evidence that the disease itself is static. Advances in multidisciplinary care, nutritional support, and respiratory management have gradually altered the natural history of these conditions, and longer survival can shift where and when deaths are recorded. Continued monitoring, ideally complemented by registry-based and clinical data, will be essential to interpret how evolving care patterns reshape the mortality landscape described here.

Subject of Research: Long-term mortality trends and geographic disparities in motor neuron disease among US adults from 1999 to 2024

Article Title: Mortality trends and geographic disparities in motor neuron disease among US adults aged 25 years and older, 1999–2024: a serial cross-sectional study using CDC WONDER

Article References: Jiang, R., Zhu, Q., Jiang, Q., Zhao, T., & Zhou, J. (2026). Mortality trends and geographic disparities in motor neuron disease among US adults aged 25 years and older, 1999–2024: a serial cross-sectional study using CDC WONDER. BMC Public Health. https://doi.org/10.1186/s12889-026-29374-x

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29374-x

Keywords: motor neuron disease, amyotrophic lateral sclerosis, mortality trends, CDC WONDER, age-adjusted mortality rate, geographic disparities, BMC Public Health, joinpoint regression, rural health, neurodegenerative disease, population aging, public health